x

Posted 11 December, 2023

Allarity Therapeutics, Inc. appointed Mr. Thomas Jensen as new CEO

Nasdaq:ALLR appointed new Chief Executive Officer Mr. Thomas Jensen in a 8-K filed on 11 December, 2023.


  On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company's Board of Directors as Chief Executive Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Allarity Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
Market Cap
$2.41M
View Company Details
Allarity Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the "Company") and all other positions with the Company and its subsidiaries.


On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company's Board of Directors as Chief Executive Officer. Since July 2022, Mr. Jensen has served as Senior Vice President, Investor Relations and was previously the Company's Senior Vice President, Information Technology since July 2021. Mr. Jensen has also served as Senior Vice President, Information Technology of Allarity Therapeutics A/S, the Company's predecessor, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of the Company's predecessor from 2004 to June 2020. Mr. Jensen co-founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads our laboratories in Denmark. Mr. Jensen is a current member of the Company's Board of Directors.


There is no family relationship between Mr. Jensen and any director or executive officer of the Company.


Prior to appointment as Chief Executive Officer, Mr. Jensen was paid consulting fees for his services to the Company. At this time, Mr. Jensen and the Company have not entered into any material plan, contract or arrangement related to his appointment.